Factors tested were those found significantly different between PGS and conventional GBM patients (temporal tumor location, MGMT promoter methylation and EoR at primary surgery) together with other variables previously demonstrated prognostic for GBM (age, PS, corticosteroid use) (Supplementary Table 4). This evidence concerns the gene MGMT and glioblastoma.